Initiator aims to develop safe and efficacious therapeutics. The company’s pipeline consists of three clinical programs, IPED2015, IP2018 and IPTN2021, and two in pre-clinical stage, IPDP2015 and IPNP2015.
The IP2015 drug candidate is being tested in two clinical indications: i) erectile dysfunction (organic) (Program called IPED2015) and ii) neuropathic pain (program called IPTN2021). IP2018 drug candidate is so far only being tested in one clinical indication: erectile dysfunction (psychogenic) (Program called IP2018). All drug candidates belong to the drug class known as monoamine reuptake inhibitors and is based on compounds modulating monoamine neurotransmitters e.g., dopamine, noradrenaline, and serotonin.
Modulation and regulation of monoamines are indeed validated and efficacious therapy for a broad range of medical conditions. The monoaminergic system plays a pivotal role in many important physiological functions, e.g., mood, pain, arousal, sexual function, and might be used to treat depression, attention deficit hyperactive disorder (ADHD), narcolepsy, and anxiety. The major challenge with targeting the monoaminergic system is ensuring that the modulation archives a safe therapeutics window, deviating from the adverse effects (AEs) known from previously and currently marketed monoamine modulation drugs, e.g., liver tox and sexual dysfunction. Initiator has a pipeline of clearly differentiated monoamine modulation drug candidates with attractive safety profiles.